江苏吴中医药发展股份有限公司关于 终止实施第一期员工持股计划并注销相关股份的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 证券代码：600200 证券简称：江苏吴中 公告编号：临 2025-025 一、已履行的主要决策程序和信息披露情况 1、2021 年 12 月 16 日，公司召开了第十届董事会 2021 年第四次临时会议 （通讯表决），审议通过了《关于<江苏吴中医药发展股份有限公司第一期员工 持股计划（草案）>及其摘要的议案》《关于<江苏吴中医药发展股份有限公司第 一期员工持股计划管理办法>的议案》《关于提请股东大会授权董事会办理公司 第一期员工持股计划有关事项的议案》等议案。 同日，公司召开第十届监事会 2021 年第三次临时会议（通讯表决），审议 了《关于<江苏吴中医药发展股份有限公司第一期员工持股计划（草案）>及其摘 要的议案》《关于<江苏吴中医药发展股份有限公司第一期员工持股计划管理办 法>的议案》等议案，公司监事会对第一期员工持股计划（以下简称"本员工持 股计划"或"本持股计划"）的相关事项进行核实并出具了相关 ...

江苏吴中医药发展股份有限公司关于 2024 年度会计师事务所履职情况的评估报告 江苏吴中医药发展股份有限公司（以下简称"公司"）聘请中兴财光华会计 师事务所（特殊普通合伙）（以下简称"中兴财光华"）作为公司 2023 年度年报 审计机构。根据财政部、国资委及证监会颁布的《国有企业、上市公司选聘会计 师事务所管理办法》，公司对中兴财光华 2023 年审计过程中的履职情况进行评估。 经评估，公司认为中兴财光华资质条件等方面合规有效，履职保持独立性，勤勉 尽责，公允表达意见，具体情况如下： 一、资质条件 中兴财光华会计师事务所（特殊普通合伙）成立于 1999 年 1 月，2013 年 11 月转制为特殊普通合伙。注册地：北京市西城区阜成门外大街 2 号万通金融中心 A 座 24 层，首席合伙人：姚庚春。截至 2024 年 12 月 31 日，事务所从业人员 2898 人，其中，注册会计师 804 人，有 331 人签署过证券服务业务报告。合伙人有 187 人。2024 年业务收入（未经审计）99,115.12 万元，其中审计业务收入（未 经审计）87,645.28 万元，证券业务收入（未经审计）39,661.81 ...

证券代码：600200 证券简称：江苏吴中 公告编号：2025-033 江苏吴中医药发展股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024年年度股东大会 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运 作》等有关规定执行。 (七) 涉及公开征集股东投票权 不适用 召开的日期时间：2025 年 5 月 21 日 14 点 30 分 召开地点：江苏省苏州市吴中区东方大道 988 号，公司会议室。 (五) 网络投票的系统、起止日期和投票时间。 股东大会召开日期：2025年5月21日 本次股东大会采用的网络投票系统：中国证券登记结算有限责任公司股 东大会网络投票系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥317,201,141.57, representing a decrease of 25.44% compared to ¥425,437,783.19 in the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥70,317,871.21, a significant decline of 1,489.93% from a profit of ¥5,059,107.81 in the previous year[4]. - The net cash flow from operating activities was negative at ¥923,950,027.41, down 14,265.46% from ¥6,522,556.86 in the same period last year[4]. - Basic and diluted earnings per share were both -¥0.099, a decrease of 1,514.29% from ¥0.007 in the previous year[6]. - The weighted average return on equity decreased by 4.22 percentage points to -3.93% from 0.29% in the previous year[6]. - Total operating revenue for Q1 2025 was CNY 317.20 million, a decrease of 25.5% compared to CNY 425.44 million in Q1 2024[19]. - Net loss for Q1 2025 was CNY 65.82 million, compared to a net profit of CNY 4.67 million in Q1 2024[21]. - The company reported a gross profit margin of 5.4% in Q1 2025, significantly lower than the previous year's margin[19]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,977,795,292.66, a slight increase of 0.07% from ¥3,974,855,380.28 at the end of the previous year[6]. - Shareholders' equity attributable to the parent company decreased by 3.85% to ¥1,752,868,642.46 from ¥1,823,069,365.96 at the end of the previous year[6]. - The company’s total liabilities as of the reporting date were CNY 2.15 billion, an increase from CNY 2.09 billion year-over-year[19]. - Total cash inflow from operating activities in Q1 2025 was $506.71 million, down from $2.20 billion in Q1 2024, representing a decrease of approximately 77%[25]. - Cash and cash equivalents decreased significantly to RMB 168,482,001.92 from RMB 1,151,522,442.64, reflecting a decline of approximately 85.3%[15]. Cash Flow and Investments - The company recorded an investment income of CNY 3.83 million in Q1 2025, a recovery from a loss of CNY 1.23 million in Q1 2024[19]. - Cash outflow for purchasing goods and services in Q1 2025 was $1.21 billion, compared to $2.01 billion in Q1 2024, indicating a reduction of about 40%[25]. - The net cash flow from financing activities in Q1 2025 was -$41.35 million, contrasting with a positive cash flow of $90.41 million in Q1 2024[26]. - The total cash outflow for investment activities in Q1 2025 was $15.14 million, significantly lower than $122.66 million in Q1 2024, indicating a reduction of about 88%[26]. Challenges and Legal Issues - The significant decline in revenue and profit was attributed to a large impairment provision for trade receivables in the current reporting period[8]. - The company is currently facing challenges in its pharmaceutical business, leading to a substantial decrease in cash flow and profitability[8]. - The company is under investigation by the China Securities Regulatory Commission, which may impact its stock listing status if found guilty of major violations[13]. - The company’s subsidiary is facing a lawsuit related to export tax fraud, with the first court hearing scheduled for April 22, 2025[13]. - Certain bank accounts have been frozen due to overdue loans, which may affect the company's financing capabilities[14]. Research and Development - Research and development expenses increased to CNY 12.23 million in Q1 2025, up from CNY 10.19 million in Q1 2024, reflecting a 19.9% increase[19]. - The company has not disclosed any new product developments or market expansion strategies in the recent reports[12].

Financial Performance - In 2024, Jiangsu Wuzhong achieved a consolidated net profit of ¥70,483,471.07, while the parent company's net profit was ¥39,864,975.54[7]. - The parent company reported an initial undistributed profit of -¥910,780,011.15 at the beginning of the year, ending with -¥870,915,035.61, resulting in no profit distribution for 2024[7]. - The company's operating revenue for 2024 was approximately ¥1.60 billion, a decrease of 28.64% compared to ¥2.24 billion in 2023[29]. - The net profit attributable to shareholders was ¥70.48 million, recovering from a loss of ¥71.95 million in the previous year[29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥51.27 million, compared to a loss of ¥98.88 million in 2023[29]. - The weighted average return on equity increased to 3.95%, up by 8.01 percentage points from -4.06% in 2023[29]. - The total assets decreased by 8.14% to approximately ¥3.97 billion from ¥4.33 billion in 2023[29]. - The company achieved operating revenue of CNY 1,598.51 million, a decrease of 28.64% compared to the previous year, with main business revenue down by 28.97%[97]. - Gross profit reached CNY 772.58 million, an increase of 42.12% year-on-year, with main business gross profit up by 43.46%[97]. - The company reported a significant increase in other income, up 296.29% to CNY 18.40 million, primarily due to government subsidies[98]. Legal and Regulatory Issues - The company is facing legal challenges, including a lawsuit against its wholly-owned subsidiary for alleged involvement in tax fraud, with the first court hearing held on April 22, 2025[12]. - The company is under scrutiny from the China Securities Regulatory Commission due to the overdue debts and potential legal implications[12]. - Jiangsu Wuzhong's financial report received an audit opinion of "unable to express" from Zhongxing Caiguanghua Accounting Firm, indicating potential concerns regarding financial accuracy[6]. Research and Development - The company has established a strict project management system for R&D, enhancing progress, quality, and procedural improvements to ensure the integrity and authenticity of R&D data[44]. - The company is actively exploring equity cooperation models and CDMO partnerships to address raw material supply constraints and expand its production capabilities[45]. - The company achieved a 100% pass rate in inspections by various drug regulatory authorities, ensuring stable production and quality management[47]. - The company is leveraging AI-driven protein design technology to shorten the development cycle of recombinant collagen, enhancing its R&D capabilities in this field[53]. - Total R&D investment amounted to ¥91,580,022.07, representing 5.73% of total operating revenue[107]. - The number of R&D personnel is 128, making up 11.7% of the total workforce[108]. - Research and development expenses increased by 55.63% to CNY 61.12 million, reflecting a focus on enhancing internal R&D capabilities[98]. Market and Product Development - The company reported a significant increase in sales from its medical beauty sector, particularly the AestheFill product, which started sales in April 2024[28]. - The company’s AestheFill product, a high-end injection for aesthetic medicine, received market approval in January 2024, with a sales team of 55 people covering 537 medical institutions by the end of 2024[50]. - AestheFill holds a nearly 30% market share in the aesthetic regenerative injection market in Taiwan, with a higher price range than similar products[49]. - The company is focusing on non-surgical aesthetic biotechnology and expanding its product pipeline in the dermal filler market, which is experiencing rapid growth due to increasing consumer acceptance[62]. - The company is actively developing new products, with three Class II medical devices receiving registration certificates from Jiangsu Provincial Drug Administration by December 2024[94]. - The company is pursuing a dual-driven strategy of self-research and external investment to expand its medical beauty product portfolio[96]. Financial Management and Governance - The company has established a comprehensive investor relations management system, enhancing communication with investors through multiple channels[182]. - The company held 9 board meetings during the reporting period, with all resolutions passed[181]. - The total pre-tax remuneration for the board members and senior management amounted to 637.54 million CNY[189]. - The company has been proactive in addressing investor feedback and suggestions to strengthen trust and transparency[182]. - The company has scheduled additional extraordinary shareholder meetings to address various governance and operational matters throughout 2024[184][188]. - The company is committed to maintaining high standards of corporate governance and compliance with regulatory requirements[192]. Industry Trends and Challenges - The pharmaceutical industry is experiencing significant challenges, with overall valuation and performance declining due to factors such as trade tensions and increased competition, yet it shows resilience through innovation and policy support[156]. - The medical beauty industry is entering a "strong regulation" era, with new policies aimed at protecting consumer rights and ensuring industry standards[79]. - The overall pharmaceutical market is expected to maintain steady growth driven by factors such as aging population and increasing income levels, supported by ongoing healthcare reforms[158]. - The light medical beauty sector is projected to grow at a CAGR of 17.5% from 2021 to 2030, significantly outpacing the surgical segment's 10.4% growth rate[159].

江苏吴中医药发展股份有限公司 第十一届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）第十一届监事会第四 次会议通知于 2025 年 4 月 18 日以书面或电子邮件等形式发出，会议于 2025 年 4 月 29 日在公司会议室举行。会议应到监事 3 人，实到监事 3 人。会议的召开 符合《公司法》和相关法律法规以及《公司章程》《监事会议事规则》的有关规 定。会议由监事会主席吴振邦先生主持，会议经过审议，以书面投票表决方式通 过了如下决议： 一、审议通过了江苏吴中医药发展股份有限公司 2024 年度监事会工作报告 表决结果：3 票同意， 0 票弃权， 0 票反对。 本议案尚需提交公司股东大会审议通过。 二、审议通过了江苏吴中医药发展股份有限公司 2024 年度报告与年报摘要 监事会经审议后认为：公司 2024 年度报告及年报摘要的编制和审议程序符 合《公司法》《上海证券交易所股票上市规则》等法律法规及《公司章程》等规 章制度的要求；年报内容和格式符合《公 ...

公司监事会将依法履行监督职责，持续关注董事会和管理层相关工作的开展， 切实维护公司及全体股东的合法权益。 江苏吴中医药发展股份有限公司 监事会 2025 年 4 月 30 日 江苏吴中医药发展股份有限公司监事会对 《董事会关于 2024 年度无法表示意见的财务报告审计 报告和内部控制审计报告的专项说明》的意见 中兴财光华会计师事务所（特殊普通合伙）对江苏吴中医药发展股份有限公 司（以下简称"公司"或"江苏吴中"）2024 年度财务报表进行了审计，并出 具了无法表示意见的审计报告。根据中国证券监督管理委员会《公开发行证券的 公司信息披露编报规则第 14 号——非标准审计意见及其涉及事项的处理》和《上 海证券交易所股票上市规则》的要求，公司监事会对董事会就会计师事务所对公 司 2024 年度财务报告无法表示意见的财务报告审计报告和内部控制审计报告的 专项说明出具如下意见： 监事会认为：中兴财光华会计师事务所出具的无法表示意见的财务报告审计 报告和内部控制审计报告客观地反映了公司 2024 年度的财务状况和经营情况， 监事会对无法表示意见审计报告无异议。公司董事会对无法表示意见审计报告的 专项说明符合公司的实际情况 ...

江苏吴中（600200）公告，2025年第一季度营收为3.17亿元，同比下降25.44%；净亏损7031.79万元， 去年同期净利润505.91万元。 ...

江苏吴中：公司股票将被实施退市风险警示及其他风险警示 智通财经4月29日电，江苏吴中(600200.SH)公告称，由于中兴财光华会计师事务所对公司2024年度财务 报告出具了无法表示意见的审计报告，公司股票将被实施退市风险警示。同时，由于该事务所对公司 2024年度出具了无法表示意见的内部控制审计报告，公司股票还将被实施其他风险警示。公司股票将于 2025年4月30日停牌一天，自2025年5月6日起被实施退市风险警示，股票简称将变更为*ST苏吴。实施 退市风险警示后，公司股票将在风险警示板交易，日涨跌幅限制为5%。 ...

New Stock Offerings - ST Xinchao (600777) has two tender offer periods: April 8 to May 7, 2025, and April 23 to May 22, 2025[1] - Puli Tui (300630) is in the delisting arrangement period with 13 trading days remaining[1] - ST Yushun (002289) and ST Jingan (600190) are also highlighted for their recent announcements[1] Market Alerts - Jinlitai (300225) has been flagged for severe abnormal fluctuations[1] - Guoguang Chain (605188) and Dongfang Tong (300379) have recent announcements regarding their trading status[1] - Multiple stocks including Huadian Energy (600726) and Huadian Liaoning (600396) have recent updates as of April 29, 2025[1] Trading Periods - The last trading day for several stocks is approaching, with specific mention of ST Yushun and ST Jingan[1] - The report indicates that various stocks are under observation due to unusual trading activities[2]